日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial

Ravulizumab治疗IgA肾病的疗效和安全性:一项II期随机双盲安慰剂对照试验

Lafayette, Richard; Tumlin, James; Fenoglio, Roberta; Kaufeld, Jessica; Pérez Valdivia, Miguel Ángel; Wu, Mai-Szu; Susan Huang, Shih-Han; Alamartine, Eric; Kim, Sung Gyun; Yee, Min; Kateifides, Andreas; Rice, Kara; Garlo, Katherine; Barratt, Jonathan

Authors' Reply: Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?

作者回复:IgA肾病中的补体抑制疗法:完全抑制还是选择性抑制?

Barratt, Jonathan; Garlo, Katherine; Kateifides, Andreas; Lafayette, Richard

Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL

载脂蛋白A-I 218-226区疏水残基和带电残基在HDL生物合成中的作用

Fotakis, Panagiotis; Kateifides, Andreas K; Gkolfinopoulou, Christina; Georgiadou, Dimitra; Beck, Melissa; Gründler, Katharina; Chroni, Angeliki; Stratikos, Efstratios; Kardassis, Dimitris; Zannis, Vassilis I

ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT

ApoA-IV 在 ABCA1 和 LCAT 的参与下促进含 ApoA-IV 的高密度脂蛋白 (HDL) 颗粒的生物合成。

Duka, Adelina; Fotakis, Panagiotis; Georgiadou, Dimitra; Kateifides, Andreas; Tzavlaki, Kalliopi; von Eckardstein, Leonard; Stratikos, Efstratios; Kardassis, Dimitris; Zannis, Vassilis I

Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL

载脂蛋白A-I的疏水性残基225-230对高密度脂蛋白生物合成的重要性

Fotakis, Panagiotis; Tiniakou, Ioanna; Kateifides, Andreas K; Gkolfinopoulou, Christina; Chroni, Angeliki; Stratikos, Efstratios; Zannis, Vassilis I; Kardassis, Dimitris

Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3

载脂蛋白AI对小肠结肠炎耶尔森菌O:3血清型具有杀菌活性。

Biedzka-Sarek, Marta; Metso, Jari; Kateifides, Andreas; Meri, Taru; Jokiranta, T Sakari; Muszyński, Artur; Radziejewska-Lebrecht, Joanna; Zannis, Vassilis; Skurnik, Mikael; Jauhiainen, Matti